Skip to main content
    S

    SAB Biotherapeutics Inc (SABS)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $3.00
    +0.04 (+1.35%)

    Market Cap: $266.66M

    Last updated: Nov 17, 2026 at 11:05 AM ET

    SAB Biotherapeutics Inc (SABS) Stock Forecast

    Updated Nov 17, 2026. Estimates and ratings come from consensus analyst data.

    Analysts expect SAB Biotherapeutics (SABS) to earn -$1.13 per share in the fiscal year ending Dec 31, 2026. Of 11 analysts, 11 rate the stock Buy or Strong Buy, 0 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 1 estimate for the fiscal year ending Dec 31, 2026 was revised up and 0 down.

    Analyst Ratings

    Scoring Strong Buy as 1 and Strong Sell as 5, the 11 ratings average 1.91, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 100% of the ratings.

    RatingAnalystsShare
    Strong Buy19.1%
    Buy1090.9%
    Hold00.0%
    Sell00.0%
    Strong Sell00.0%
    Consensus
    Buy
    Total analysts
    11

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Annual Estimates

    From the first fiscal year below to the second, the EPS consensus shows a smaller loss.

    Fiscal year ending Dec 31, 2026
    -$1.13
    EPS consensus
    Fiscal year ending Dec 31, 2027
    -$0.94
    EPS consensus
    Next report
    Mar 8, 2027
    Estimated

    EPS range

    Fiscal year endingEPS consensusEPS rangeEPS analysts
    Dec 31, 2026-$1.13-$1.16 to -$1.063
    Dec 31, 2027-$0.94-$1.20 to -$0.605

    Quarterly Estimates

    The EPS consensus is -$0.25 for both quarters below, ending Dec 31, 2026 and Mar 31, 2027.

    EPS range

    Quarter endingEPS consensusEPS rangeEPS analysts
    Dec 31, 2026-$0.25-$0.30 to -$0.1113
    Mar 31, 2027-$0.25-$0.32 to -$0.213

    Estimate Revisions

    Across the 3 periods below, the last 30 days brought 2 upward and 0 downward EPS revisions.

    PeriodUp 30 daysDown 30 days
    Fiscal year ending Dec 31, 202610
    Fiscal year ending Dec 31, 202710
    Quarter ending Mar 31, 202700

    EPS Trend

    Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has improved from -$1.16.

    PeriodNow7 days ago30 days ago60 days ago90 days agoChange
    Fiscal year ending Dec 31, 2026-$1.13-$1.16-$1.16-$1.16-$1.16N/A
    Fiscal year ending Dec 31, 2027-$0.94-$0.95-$0.95-$0.95-$0.95N/A
    Quarter ending Mar 31, 2027-$0.25-$0.21-$0.21-$0.21-$0.21N/A

    Frequently Asked Questions About SABS

    What is the SABS stock forecast?

    Consensus analyst estimates put SAB Biotherapeutics's EPS at -$1.13 for the fiscal year ending Dec 31, 2026. The consensus rating from 11 analysts is Buy.

    How do analysts rate SABS stock?

    Of 11 analysts covering SAB Biotherapeutics, 1 rates it Strong Buy, 10 Buy, 0 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.

    What EPS do analysts expect from SABS next year?

    For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$1.13, with estimates from -$1.16 to -$1.06 from 3 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$0.94, with estimates from -$1.20 to -$0.60 from 5 analysts.

    How many analysts cover SABS?

    11 analysts rate SAB Biotherapeutics stock, and 3 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.